Search
Confirm
Cancel
News

News

Fusen Pharmaceutical Stock code:1652.HK
Location:
Homepage
-
-
-
Good news! Fusen Pharmaceutical Co., Ltd. was listed as the "top 100 Chinese patent medicine enterprises in 2021"

Good news! Fusen Pharmaceutical Co., Ltd. was listed as the "top 100 Chinese patent medicine enterprises in 2021"

  • Categories:Company News
  • Author:
  • Origin:
  • Time of issue:2021-12-27
  • Views:

(Summary description)

Good news! Fusen Pharmaceutical Co., Ltd. was listed as the "top 100 Chinese patent medicine enterprises in 2021"

(Summary description)

  • Categories:Company News
  • Author:
  • Origin:
  • Time of issue:2021-12-27 14:51
  • Views:
Information

Recently, at the traditional Chinese medicine industry information conference of China traditional Chinese Medicine Association, the top 100 list of Chinese patent medicine enterprises in 2021 was released, and Fusen pharmaceutical was listed on the list.

Top 100 list of Chinese patent medicine enterprises

According to Liu Zhanglin, vice president of China traditional Chinese Medicine Association, the shortlisted enterprises reached 740 million yuan, an increase of 290 million over 2020. Among them, there are 10 enterprises exceeding 10 billion, an increase of 5 over the previous year, 75 production enterprises between 1 billion and 10 billion, an increase of 14 over the same period of the previous year, 15 shortlisted enterprises less than 1 billion, a decrease of 19 over the same period of the previous year, indicating that the number of enterprises with core competitiveness in the traditional Chinese medicine industry is increasing year by year.


This listing is a recognition of the strong strength of Fusen pharmaceutical and the future growth potential of Fusen pharmaceutical.


Introduction to Fusen pharmaceutical

▲ Fusen pharmaceutical


Fusen Pharmaceutical Co., Ltd. is a modern comprehensive pharmaceutical enterprise integrating herbal medicine planting, drug R & D, production and sales. Since the restructuring in 2003, Fusen pharmaceutical, adhering to the concept of "honesty and trustworthiness, strengthening the foundation, winning the brand and steady development", has won the titles of "national leading enterprise of agricultural industrialization" and "excellent private enterprise" and "high-tech enterprise" in Henan Province. In 2018, Fusen pharmaceutical was listed on the main board of the Hong Kong stock exchange, stock code: 1652 HK。

In the future, Fusen pharmaceutical will continue to carry forward the culture of traditional Chinese medicine, develop more and better products, help the development of traditional Chinese medicine industry, and adhere to the business philosophy of "ingenuity, quality, health is happiness" to protect the health of consumers.

Related News

Fusen

Fusen pharmaceutical: metformin hydrochloride sustained release tablets passed the consistency evaluation

Fusen pharmaceutical metformin hydrochloride sustained-release tablets have successfully passed the evaluation of the consistency of quality and efficacy of generic drugs! Metformin Hydrochloride Sustained Release Tablets, a diabetes drug, has been approved by the State Administration for drug control. This product has successfully passed the quality and efficacy consistency evaluation of generic drugs, which is an authoritative recognition of the R & D capacity, production and quality management system and clinical efficacy of Fusen pharmaceutical, further highlights the product brand of Fusen pharmaceutical, helps to improve the market competitiveness of the drug, and accumulates valuable experience for the company's follow-up products to carry out generic drug consistency evaluation. ▲ notice of approval from the State Drug Administration Metformin Hydrochloride Tablets is the basic medicine for diabetes. It is used for diet and physical exercise to control type 2 diabetes patients with blood glucose inefficacy, especially obesity and hyperinsulinemia. As a first-line drug for the treatment of type II diabetes, metformin is often used in combination with other oral hypoglycemic agents. ▲ for medical professionals only Because of the superiority of metformin, it is listed as the first-line treatment for hypoglycemic treatment in the guidelines for prevention and treatment of type II diabetes, formulated by professional academic organizations both at home and abroad. As the holder of drug marketing license, Fusen pharmaceutical will not forget its original intention, forge ahead, strictly control the product quality, and constantly optimize the product layout, so that more drugs of Fusen pharmaceutical can benefit the majority of patients.
2022-04-26
Jiaheng

Jiaheng pharmaceutical was approved to set up a post doctoral research workstation sub station

Recently, the Department of human resources and social security of Guangdong Province issued a notice that the National Postdoctoral Management Committee approved Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd., a wholly-owned subsidiary of Fusen pharmaceutical, to set up a postdoctoral scientific research workstation branch. ▲ exhibition hall of Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd ▲ exhibition hall of Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd. is a research and development subsidiary established by Fusen pharmaceutical in response to the national development strategy of traditional Chinese medicine. In order to enhance the independent research and development ability of traditional Chinese medicine, take the research and development of high-quality and effective traditional Chinese medicine as the main goal, and integrate the high-quality traditional Chinese medicine resources in the industry. ▲ Guangdong Macao science and Technology Industrial Park of traditional Chinese Medicine The company is located in Hengqin Guangdong Macao cooperative traditional Chinese medicine science and Technology Industrial Park. It is the first R & D platform settled in the industrial park and officially operated after the establishment of Hengqin Guangdong Macao deep cooperation zone. It is the supporting unit of the large variety cultivation sub center of traditional Chinese medicine of the national traditional Chinese medicine modernization engineering technology center. Its main business is the R & D of innovative traditional Chinese medicine and secondary development of traditional Chinese medicine, chemical medicine raw materials and preparations, light medicine and beauty products and great health products. This time, Jiaheng pharmaceutical was approved to set up a post doctoral research workstation sub station, which is an affirmation of Jiaheng pharmaceutical's technological innovation ability and R & D ability, creates conditions for the company's talent training and the improvement of technological innovation ability, is conducive to further promoting the company's cooperation with universities and scientific research institutes, is conducive to the introduction of high-end R & D talents, is conducive to further improving the company's independent R & D ability and realizing the landing and transformation of scientific research achievements, Promote the sustainable innovation and development of the company and continuously improve the core competitiveness of the company.
2022-04-19

WeChat

福森药业

Copyright © 2021 Fusen Pharmaceutical Company Limited

豫ICP备2021028871号  Powered by www.300.cn

Copyright © 2021 Fusen Pharmaceutical  All Rights Reserved.      豫ICP备2021028871号        Powered by www.300.cn